Get the Stockscreener App
10.30
0.98%
0.10
After Hours:
10.30
Translational Development Acquisition Corp stock is traded at $10.30, with a volume of 2,000.
It is up +0.98% in the last 24 hours and up +1.58% over the past month.
Translational Development Acquisition Corp is a newly organized blank check company.
See More
Previous Close:
$10.20
Open:
$10.25
24h Volume:
2,000
Relative Volume:
0.08
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.98%
1M Performance:
+1.58%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.20
$10.30
1-Week Range:
$10.17
$10.30
52-Week Range:
$10.00
$10.30
Translational Development Acquisition Corp Stock (TDACU) Company Profile
Name
Translational Development Acquisition Corp
Sector
Industry
Phone
(413) 204-2769
Address
52 E 83RD ST., NEW YORK
Compare TDACU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TDACU
Translational Development Acquisition Corp
|
10.30 | 0 | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
6.83 | 2.01B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
AACT
Ares Acquisition Corporation Ii
|
11.26 | 695.30M | 0 | 16.92M | -1.35M | 0.29 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.72 | 461.01M | 0 | 1.30M | 0 | 0.0301 |
|
AAM
Aa Mission Acquisition Corp
|
10.31 | 453.37M | 0 | 0 | 0 | 0.00 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.20 | 453.30M | 0 | 0 | 0 | 0.00 |
Translational Development Acquisition Corp Stock (TDACU) Latest News
Secretome Therapeutics Appoints New Chief Medical Officer - Dallas Innovates
Secretome Therapeutics Appoints Dr. Marshelle Smith Warren as Chief Medical Officer - BioSpace
Artis BioSolutions Emerges from Stealth, Announces Acquisition of Landmark Bio - BioSpace
Translational Development Acquisition Corp. (TDAC) reports earnings - Quartz
Pioneering Innovative Drug Development at Cambridge Crossing Facility - Bristol Myers Squibb
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - BioSpace
Stock market today: Wall Street finishes a winning week just shy of a record - 69News WFMZ-TV
Translational Development Acquisition Corp. Announces that the Separate Trading of its Class A Ordinary Shares and Warrants has Commenced - Yahoo Finance
Quaker Oats recalls 10,000 boxes of Pearl Milling Company pancake mix for milk allergy risk - 69News WFMZ-TV
Major SPAC Update: TDACU Splits Units into Separate Shares & Warrants Trading - Stock Titan
Trident Acquisitions stock hits 52-week high of $10.08 - MSN
Trident Acquisitions stock hits 52-week high of $10.08 By Investing.com - Investing.com South Africa
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development - GlobeNewswire
ImmuPharma (LON:IMM) Stock Price Up 9.3% – Here’s Why - Defense World
Rockhopper Exploration (LON:RKH) Shares Down 8% – Here’s What Happened - Defense World
Health In Tech, Inc.’s (NASDAQ:HIT) Quiet Period To End on February 3rd - Defense World
Translational Development Acquisition Corp.’s Quiet Period Set To Expire on February 3rd (NASDAQ:TDACU) - Defense World
Research Analysts Issue Forecasts for BHC FY2025 Earnings - Defense World
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
TDACU stock touches 52-week low at $10.01 amid market shifts - Investing.com Canada
NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Trident Acquisitions stock hits 52-week high at $10.04 - Investing.com Australia
Trident Acquisitions stock hits 52-week high at $10.04 By Investing.com - Investing.com UK
Translational Development Acquisition Corp. Announces Closing of $172.5 Million Initial Public Offering, Including Full Exercise of Underwriter's Over-Allotment Option - Finansavisen
Translational Development (TDACU) Raises $172.5M in Successful Nasdaq IPO, Begins Trading - Stock Titan
Translational Development Acquisition Corp. Announces the Pricing of $150,000,000 Initial Public Offering - The Eastern Progress Online
Translational Development Acquisition Corp Launches $150M IPO on Nasdaq, Units to Trade as TDACU - StockTitan
Translational Development Acquisition Corp. (TDACU) Prices $150M IPO - SPACInsider
What’s next for the man charged with killing UnitedHealthcare’s CEO? - 69News WFMZ-TV
Italy's privacy watchdog fines OpenAI for ChatGPT's violations in collecting users personal data - 69News WFMZ-TV
For airports, background music no longer is an afterthought - 69News WFMZ-TV
The Fed expects to cut rates more slowly in 2025. What that could mean for mortgages, debt and more - 69News WFMZ-TV
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
(PDF) Translational Science: A Road Map for the Science of Reading - ResearchGate
Rapid effects of valproic acid on the fetal brain transcriptome: implications for brain development and autism - Nature
Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel - GlobeNewswire
Deal Watch: Dealmakers Brace for Impact of Presidential Election - Law.com
IPO NewsUS IPO Weekly Recap: Sizable tech and biotech IPOs are joined by a flurry of small names - Renaissance Capital
(PDF) Measuring Translation Competence Acquisition - ResearchGate
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities - GlobeNewswire
Ipsen and Foreseen Biotechnology announce exclusive global - GlobeNewswire
Research and development center Cambridge, Massachusetts - Bristol Myers Squibb
Iron controls the development of airway hyperreactivity by regulating ILC2 metabolism and effector function - Science
Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer - PR Newswire
Novartis Acquires Mariana Oncology To Advance Radiopharmaceuticals For Cancer Treatment - Pharmaceutical Online
Rounding up the pharma firms investing the most in 2023 - Drug Discovery & Development
NanoString Technologies to Be Acquired by Bruker Corporation - Business Wire
Initial Public Offering (IPO) News Live Feed - StockTitan
Translational Development Acquisition Corp Stock (TDACU) Financials Data
There is no financial data for Translational Development Acquisition Corp (TDACU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.41%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):